It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Nonsteroidal anti-inflammatory drugs compose one of the most widely used classes of medications, but the risks for early development remain controversial, especially in the nervous system. Here, we utilized zebrafish larvae to assess the potentially toxic effects of nonsteroidal anti-inflammatory drugs and found that sulindac can selectively induce apoptosis of GABAergic neurons in the brains of zebrafish larvae brains. Zebrafish larvae exhibit hyperactive behaviour after sulindac exposure. We also found that akt1 is selectively expressed in GABAergic neurons and that SC97 (an Akt1 activator) and exogenous akt1 mRNA can reverse the apoptosis caused by sulindac. Further studies showed that sulindac binds to retinoid X receptor alpha (RXRα) and induces autophagy in GABAergic neurons, leading to activation of the mitochondrial apoptotic pathway. Finally, we verified that sulindac can lead to hyperactivity and selectively induce GABAergic neuron apoptosis in mice. These findings suggest that excessive use of sulindac may lead to early neurodevelopmental toxicity and increase the risk of hyperactivity, which could be associated with damage to GABAergic neurons.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used but their risks for early neurodevelopment remain controversial. Here, the authors showed in zebrafish larvae that sulindac induces GABAergic neuron apoptosis through autophagy activation that leads to hyperactive behavior.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details















1 South China University of Technology, Division of Cell, Developmental and Integrative Biology, School of Medicine, Guangzhou, China (GRID:grid.79703.3a) (ISNI:0000 0004 1764 3838)
2 South China University of Technology, National Engineering Research Center for Tissue Restoration and Reconstruction, Key Laboratory of Biomedical Engineering of Guangdong Province, Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, Innovation Center for Tissue Restoration Reconstruction, Guangzhou, China (GRID:grid.79703.3a) (ISNI:0000 0004 1764 3838)
3 Guangdong Pharmaceutical University, Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Guangzhou, China (GRID:grid.411847.f) (ISNI:0000 0004 1804 4300)
4 Clear Water Bay, Kowloon, Division of Life Science, State Key Laboratory of Molecular Neuroscience and Center of Systems Biology and Human Health, the Hong Kong University of Science and Technology, Hong Kong, People’s Republic of China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450); Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, Greater Bay Biomedical Innocenter, Shenzhen Bay Laboratory, Shenzhen, China (GRID:grid.510951.9) (ISNI:0000 0004 7775 6738)
5 South China University of Technology, Division of Cell, Developmental and Integrative Biology, School of Medicine, Guangzhou, China (GRID:grid.79703.3a) (ISNI:0000 0004 1764 3838); Shenzhen Bay Laboratory, Greater Bay Biomedical Innocenter, Shenzhen, China (GRID:grid.510951.9) (ISNI:0000 0004 7775 6738)